BioCentury | Jun 27, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on LINC00477 and HCN4 could help predict the risk of atrial fibrillation. Genome-wide association studies in a total of 53,174 individuals of European ancestry identified associations between low heart rate variability and...
BioCentury | Apr 15, 2013
Company News

Immtech International Inc., Pharm-Eco Laboratories Inc. deal

The companies formed a joint venture to manufacture and commercialize compounds developed by a research consortium led by the University of North Carolina, Chapel Hill (See BioCentury, March 24). Immtech gains transfer rights to commercialize...
BioCentury | Oct 24, 2011
Financial News

Deepbridge Innovation Fund financial update

Deepbridge Innovation Fund , location undisclosed Business: Finance Date announced: 10/18/11 Deepbridge Capital and asset manager SL Investment Management launched the Deepbridge Innovation Fund (DBIF) to invest in life sciences, "eco-innovation" and software, with a target...
BioCentury | Oct 19, 2011
Financial News

New Deepbridge Innovation Fund targeting $250M

Deepbridge Capital and asset manager SL Investment Management launched the Deepbridge Innovation Fund (DBIF) to invest in life sciences, "eco-innovation" and software, with a target of $250 million. The partners said the fund will target...
BioCentury | Feb 21, 2011
Clinical News

Saizen somatropin: Postmarketing study started

...Merck's Merck Serono S.A. unit began the international postmarketing ECOS trial to evaluate patient adherence to...
BioCentury | Aug 2, 2010
Company News

Helixis, Illumina deal

Illumina disclosed in its 2Q10 earnings that it acquired genetic analysis services company Helixis in April for $70 million in cash and up to $35 million in milestones. Helixis CEO Alex Dickinson became SVP of...
BioCentury | Jul 27, 2010
Company News

Illumina acquires Helixis, beats Street

Illumina Inc. (NASDAQ:ILMN) disclosed in its 2Q10 earnings that it acquired genetic analysis services company Helixis Inc. (Carlsbad, Calif.) in April for $70 million in cash and up to $35 million in milestones. Illumina gained...
BioCentury | Jan 4, 2010
Clinical News

TLN-4601: Phase II discontinued

Thallion discontinued an open-label Phase II trial after a planned interim analysis showed that only 3 out of 17 evaluable patients treated with 480 mg/m 2/day IV TLN-4601 demonstrated stable disease after two 3-week cycles...
BioCentury | Sep 29, 2008
Clinical News

TLN-4601: Phase II started

Thallion began an open-label, North American Phase II trial to evaluate 480 mg/m 2/day of intravenous TLN-4601 given for 2 weeks as part of a 21-day cycle in up to 40 patients as a second...
BioCentury | May 19, 2008
Clinical News

TLN-4601: Phase II start

This quarter, Thallion plans to start an open-label, North American Phase II trial in up to 40 patients to evaluate 480mg/m 2/day of intravenous TLN-4601 given for 2 weeks on and 1 week off in...
Items per page:
1 - 10 of 37
BioCentury | Jun 27, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on LINC00477 and HCN4 could help predict the risk of atrial fibrillation. Genome-wide association studies in a total of 53,174 individuals of European ancestry identified associations between low heart rate variability and...
BioCentury | Apr 15, 2013
Company News

Immtech International Inc., Pharm-Eco Laboratories Inc. deal

The companies formed a joint venture to manufacture and commercialize compounds developed by a research consortium led by the University of North Carolina, Chapel Hill (See BioCentury, March 24). Immtech gains transfer rights to commercialize...
BioCentury | Oct 24, 2011
Financial News

Deepbridge Innovation Fund financial update

Deepbridge Innovation Fund , location undisclosed Business: Finance Date announced: 10/18/11 Deepbridge Capital and asset manager SL Investment Management launched the Deepbridge Innovation Fund (DBIF) to invest in life sciences, "eco-innovation" and software, with a target...
BioCentury | Oct 19, 2011
Financial News

New Deepbridge Innovation Fund targeting $250M

Deepbridge Capital and asset manager SL Investment Management launched the Deepbridge Innovation Fund (DBIF) to invest in life sciences, "eco-innovation" and software, with a target of $250 million. The partners said the fund will target...
BioCentury | Feb 21, 2011
Clinical News

Saizen somatropin: Postmarketing study started

...Merck's Merck Serono S.A. unit began the international postmarketing ECOS trial to evaluate patient adherence to...
BioCentury | Aug 2, 2010
Company News

Helixis, Illumina deal

Illumina disclosed in its 2Q10 earnings that it acquired genetic analysis services company Helixis in April for $70 million in cash and up to $35 million in milestones. Helixis CEO Alex Dickinson became SVP of...
BioCentury | Jul 27, 2010
Company News

Illumina acquires Helixis, beats Street

Illumina Inc. (NASDAQ:ILMN) disclosed in its 2Q10 earnings that it acquired genetic analysis services company Helixis Inc. (Carlsbad, Calif.) in April for $70 million in cash and up to $35 million in milestones. Illumina gained...
BioCentury | Jan 4, 2010
Clinical News

TLN-4601: Phase II discontinued

Thallion discontinued an open-label Phase II trial after a planned interim analysis showed that only 3 out of 17 evaluable patients treated with 480 mg/m 2/day IV TLN-4601 demonstrated stable disease after two 3-week cycles...
BioCentury | Sep 29, 2008
Clinical News

TLN-4601: Phase II started

Thallion began an open-label, North American Phase II trial to evaluate 480 mg/m 2/day of intravenous TLN-4601 given for 2 weeks as part of a 21-day cycle in up to 40 patients as a second...
BioCentury | May 19, 2008
Clinical News

TLN-4601: Phase II start

This quarter, Thallion plans to start an open-label, North American Phase II trial in up to 40 patients to evaluate 480mg/m 2/day of intravenous TLN-4601 given for 2 weeks on and 1 week off in...
Items per page:
1 - 10 of 37